ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 194 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 0.57 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $637,231 | -91.5% | 13,698 | -92.3% | 0.00% | -93.9% |
| Q4 2020 | $7,464,000 | -30.3% | 177,288 | -24.2% | 0.03% | -21.4% |
| Q3 2020 | $10,704,000 | +25.2% | 233,820 | +37.3% | 0.04% | -2.3% |
| Q2 2020 | $8,551,000 | -15.4% | 170,324 | -13.4% | 0.04% | -34.8% |
| Q1 2020 | $10,111,000 | -45.5% | 196,605 | -34.5% | 0.07% | +8.2% |
| Q4 2019 | $18,540,000 | +4.3% | 300,085 | +1.4% | 0.06% | -7.6% |
| Q3 2019 | $17,781,000 | +100.3% | 295,954 | +181.3% | 0.07% | +106.2% |
| Q2 2019 | $8,878,000 | +30.7% | 105,211 | +48.0% | 0.03% | +23.1% |
| Q1 2019 | $6,792,000 | +198.8% | 71,111 | +121.6% | 0.03% | +160.0% |
| Q4 2018 | $2,273,000 | -61.1% | 32,088 | -53.1% | 0.01% | -52.4% |
| Q3 2018 | $5,847,000 | -60.7% | 68,417 | -46.7% | 0.02% | -65.6% |
| Q2 2018 | $14,872,000 | -33.3% | 128,317 | -53.5% | 0.06% | -40.2% |
| Q1 2018 | $22,310,000 | – | 275,742 | – | 0.10% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 862,848 | $42,556,000 | 14.73% |
| Fairmount Funds Management LLC | 171,147 | $8,441,000 | 3.56% |
| ARMISTICE CAPITAL, LLC | 1,648,000 | $81,279,000 | 1.87% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,995,000 | $98,393,000 | 0.49% |
| Jackson Creek Investment Advisors LLC | 21,409 | $1,056,000 | 0.37% |
| Hennion & Walsh Asset Management, Inc. | 113,940 | $5,620,000 | 0.34% |
| Virtus ETF Advisers LLC | 14,721 | $726,000 | 0.31% |
| Granahan Investment Management | 193,416 | $9,539,000 | 0.20% |
| Yorktown Management & Research Co Inc | 4,500 | $222,000 | 0.18% |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 242,257 | $11,948,000 | 0.09% |